BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 32546242)

  • 21. Efficacy of anakinra for idiopathic and non-idiopathic pericarditis refractory or intolerant to conventional therapy.
    Shaukat MH; Singh S; Davis K; Torosoff M; Peredo-Wende R
    Eur Heart J Acute Cardiovasc Care; 2020 Dec; 9(8):888-892. PubMed ID: 32159368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
    de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
    Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review and meta-analysis of randomized controlled trials evaluating pharmacologic therapies for acute and recurrent pericarditis.
    Melendo-Viu M; Marchán-Lopez Á; Guarch CJ; Roubín SR; Abu-Assi E; Meneses RT; Ynsaurriaga FA; Hernandez AV; Bueno H
    Trends Cardiovasc Med; 2023 Jul; 33(5):319-326. PubMed ID: 35131416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial.
    Brucato A; Imazio M; Gattorno M; Lazaros G; Maestroni S; Carraro M; Finetti M; Cumetti D; Carobbio A; Ruperto N; Marcolongo R; Lorini M; Rimini A; Valenti A; Erre GL; Sormani MP; Belli R; Gaita F; Martini A
    JAMA; 2016 Nov; 316(18):1906-1912. PubMed ID: 27825009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence.
    Lazaros G; Imazio M; Brucato A; Vassilopoulos D; Vasileiou P; Gattorno M; Tousoulis D; Martini A
    J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):256-62. PubMed ID: 26090915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020.
    Tombetti E; Mulè A; Tamanini S; Matteucci L; Negro E; Brucato A; Carnovale C
    Curr Cardiol Rep; 2020 Jun; 22(8):59. PubMed ID: 32562029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colchicine for steroid-resistant recurrent pericarditis in a child.
    Shin JH; Lee DH; Choi HJ
    Yeungnam Univ J Med; 2018 Dec; 35(2):222-226. PubMed ID: 31620598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors.
    Lo Presti S; Elajami TK; Reyaldeen R; Anthony C; Imazio M; Klein AL
    J Am Heart Assoc; 2021 Oct; 10(19):e021685. PubMed ID: 34569270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of an interleukin-1β receptor antagonist (anakinra) in idiopathic recurrent pericarditis.
    Scardapane A; Brucato A; Chiarelli F; Breda L
    Pediatr Cardiol; 2013; 34(8):1989-91. PubMed ID: 23052671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anakinra as rescue therapy for steroid-dependent idiopathic recurrent pericarditis in children: case report and literature review.
    Rodriguez-Gonzalez M; Ruiz-Gonzalez E; Castellano-Martinez A
    Cardiol Young; 2019 Feb; 29(2):241-243. PubMed ID: 30511600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schnitzler's Syndrome-Diagnostic Experience, Approaches to Therapy, and Patient Management according to a Multicenter Russian Cohort.
    Salugina SO; Torgashina AV; Borzova EY; Rameev VV; Gorodetsky VR; Fedorov ES; Muravyova NV
    Dokl Biochem Biophys; 2024 Jun; ():. PubMed ID: 38861148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
    Karabulut Y; Gezer HH; Duruöz MT
    Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in pharmacotherapy for acute and recurrent pericarditis.
    Vecchié A; Del Buono MG; Mauro AG; Cremer PC; Imazio M; Klein AL; Abbate A; Dentali F; Bonaventura A
    Expert Opin Pharmacother; 2022 Apr; 23(6):681-691. PubMed ID: 35311434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists.
    Imazio M; Lazaros G; Gattorno M; LeWinter M; Abbate A; Brucato A; Klein A
    Eur Heart J; 2022 Aug; 43(31):2946-2957. PubMed ID: 34528670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute recurrent pericarditis: from pathophysiology towards new treatment strategy.
    Cacoub P; Marques C
    Heart; 2020 Jul; 106(14):1046-1051. PubMed ID: 32238419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
    Ruperto N; Quartier P; Wulffraat N; Woo P; Ravelli A; Mouy R; Bader-Meunier B; Vastert SJ; Noseda E; D'Ambrosio D; Lecot J; Chakraborty A; Martini A; Chioato A;
    Arthritis Rheum; 2012 Feb; 64(2):557-67. PubMed ID: 21953497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
    Moran A; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Greenbaum CJ; Herold KC; Marks JB; Raskin P; Sanda S; Schatz D; Wherrett DK; Wilson DM; Krischer JP; Skyler JS; ; Pickersgill L; de Koning E; Ziegler AG; Böehm B; Badenhoop K; Schloot N; Bak JF; Pozzilli P; Mauricio D; Donath MY; Castaño L; Wägner A; Lervang HH; Perrild H; Mandrup-Poulsen T;
    Lancet; 2013 Jun; 381(9881):1905-15. PubMed ID: 23562090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent pericarditis: new and emerging therapeutic options.
    Imazio M; Lazaros G; Brucato A; Gaita F
    Nat Rev Cardiol; 2016 Feb; 13(2):99-105. PubMed ID: 26259934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety.
    Correia ETO; Dos Santos Barbetta LM; de Almeida JPCL; Mesquita ET
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):42-49. PubMed ID: 32265370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease.
    Tomelleri A; Cavalli G; De Luca G; Campochiaro C; D'Aliberti T; Tresoldi M; Dagna L
    Front Immunol; 2018; 9():1233. PubMed ID: 29910817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.